Phio Pharmaceuticals Stock Price, News & Analysis

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company in the pharmaceutical preparation manufacturing industry. The company is advancing its proprietary INTASYL® gene silencing technology, with a focus on immuno-oncology therapeutics designed to eliminate cancer. According to multiple company disclosures, Phio’s INTASYL compounds are designed to enhance the body’s immune cells so they can more effectively kill cancer cells.

Phio is based in King of Prussia, Pennsylvania, and its common stock trades on the Nasdaq Capital Market under the ticker symbol PHIO. The company describes itself as clinical-stage, meaning its drug candidates are undergoing clinical testing but are not yet approved for commercial sale. Its work centers on small interfering RNA (siRNA) technology formulated as INTASYL compounds that silence specific genes linked to cancer biology.

Core technology: INTASYL siRNA gene silencing

Across its press releases and SEC filings, Phio consistently highlights INTASYL® siRNA gene silencing technology as its core platform. This technology is described as a way to down-regulate gene expression and silence target genes in order to improve the effectiveness of immune cells against tumors. The company states that its INTASYL compounds are designed to be delivered intratumorally and to modulate genes that reduce the body’s ability to fight cancer.

Phio’s disclosures emphasize that INTASYL compounds are intended to work directly within immune cells and tumor tissue to silence specific genes. The company has presented this technology at scientific and investor conferences, including podium presentations on “INTASYL Synthesized siRNA Drug Technology” and related topics, underscoring that gene silencing and immuno-oncology are central to its business.

Lead program: PH-762 for skin cancers

The company’s lead clinical program is an INTASYL compound known as PH-762. Phio repeatedly describes PH-762 as a potent silencer of the PD-1 gene, which it states is implicated in various forms of skin cancer. PH-762 is being developed as an intratumoral immunotherapy, with the goal of enhancing anti-tumor immune responses by targeting PD-1 at the gene level.

Phio reports that PH-762 is being evaluated in an ongoing Phase 1b dose escalation clinical trial (NCT 06014086). This trial is designed to assess the neoadjuvant use of intratumoral PH-762 in patients with:

• Cutaneous squamous cell carcinoma (cSCC) – Stages 1, 2 and 4
• Stage 4 melanoma
• Stage 4 Merkel cell carcinoma

According to company communications, patients in this trial receive four injections of PH-762 at weekly intervals, and pathologic response is assessed approximately five weeks (day 36) after the initial injection. The company has disclosed that 18 patients with cutaneous carcinomas have completed treatment across five dose-escalating cohorts in this Phase 1b study.

Clinical observations reported by the company

Phio has released interim pathology data from the PH-762 trial. The company states that, among 16 patients with cSCC who completed treatment and had evaluable pathologic responses, there were:

• Six patients with a complete response (described as 100% tumor clearance)
• Two patients with a near complete response (described as > 90% clearance)
• Two patients with a partial response (described as > 50% clearance)

Phio also reports that one patient with metastatic Merkel cell carcinoma had a partial response (> 50% clearance), while six patients with cSCC and one patient with metastatic melanoma had a pathologic non-response (< 50% clearance). The company has emphasized that, in the data it has reported to date, no patients in the study exhibited clinical progression of disease during the observation window described.

On the safety side, Phio’s disclosures state that there have been no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects in patients receiving intratumoral PH-762 in the Phase 1b trial, including at the maximum dose cohort. The company notes that PH-762 has been well tolerated across all dose-escalating cohorts reviewed by its Safety Monitoring Committee.

Regulatory and development steps

In its public statements and Form 8-K filings, Phio has described several key development milestones for PH-762. The company announced that the U.S. Food and Drug Administration (FDA) accepted its nonclinical protocol study design for a toxicology study related to PH-762. Phio states that this toxicology study is required by the FDA prior to commencing a human pivotal trial and that it plans to initiate this study in the first quarter of 2026.

The company also reports entering into a drug substance development services agreement with a U.S. manufacturing company for analytical and process development and cGMP manufacture of clinical supplies for PH-762. Phio has indicated that it is working toward delivery of commercially viable drug product that meets FDA current Good Manufacturing Practices, as part of its preparation for later-stage clinical development.

Corporate and financing activities

Phio’s SEC filings describe several warrant inducement and financing transactions. The company has entered into inducement letter agreements with holders of existing warrants to exercise those warrants for cash, in exchange for new unregistered warrants. These transactions are described in detail in Forms 8-K filed on July 30, 2025 and November 6, 2025, and in related press releases. The company indicates that the gross proceeds from these warrant exercises are expected to support working capital and to fund development activities for PH-762, including clinical and manufacturing work.

Phio also reports that it uses a placement agent for certain financing activities and has issued placement agent warrants as part of these arrangements. The company’s financial disclosures describe its operating expenses, net loss, and cash position as of specific reporting dates, reflecting the costs of advancing its clinical programs and general corporate functions.

Governance and stockholder matters

Phio’s definitive proxy statement and related Form 8-K filings provide insight into its corporate governance. The company holds an annual meeting of stockholders, where stockholders vote on the election of directors, ratification of the independent registered public accounting firm, amendments to the long-term incentive plan, and advisory votes on executive compensation and the frequency of such votes.

In its proxy materials, Phio describes an amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares of common stock available for issuance. Stockholders approved this amendment, along with other proposals, at the 2025 Annual Meeting. The company has also disclosed changes in board composition, including the resignation of a director and the appointment of a Lead Independent Director, as reported in its October 31, 2025 Form 8-K.

Engagement with the scientific and investment communities

Phio regularly participates in scientific conferences and investor events. The company has announced podium and poster presentations at meetings such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the Advanced Therapies USA Congress, where it presents data and updates on INTASYL technology and PH-762. It also presents at investor-focused conferences and virtual roadshows, as described in its press releases and 8-K filings.

In addition, Phio has reported that its INTASYL compound PH-762 received recognition in an external award program, being named the “Immunomodulatory Solution of the Year” in the BioTech Breakthrough Awards. This recognition is mentioned in a company press release, which also notes that the award is part of a broader program evaluating life science and biotechnology companies and products.

Business focus and risk considerations

Overall, Phio Pharmaceuticals describes its business focus as the development of siRNA-based immuno-oncology therapeutics built on its INTASYL gene silencing platform, with PH-762 as its lead program targeting PD-1 in skin cancers. As a clinical-stage company, Phio’s disclosures emphasize ongoing research and development, regulatory interactions, clinical trial progress, and financing activities necessary to support its operations.

Like other companies at a similar stage, Phio’s press releases include cautionary language noting that forward-looking statements are subject to uncertainties, risks, and changes in circumstances that may cause actual results to differ materially from expectations. Investors and observers are directed in those documents to consider these risks when evaluating the company’s development programs and financial condition.